Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:70004
Name myeloid neoplasm
Definition A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 K650E FGFR3 over exp HRAS K117E AZ8010 myeloid neoplasm sensitive detail...
FGFR3 wild-type SSR128129E myeloid neoplasm sensitive detail...
FGFR3 K650E SSR128129E myeloid neoplasm no benefit detail...
FGFR3 Y373C Debio 1347 myeloid neoplasm sensitive detail...
FGFR3 K650E Debio 1347 myeloid neoplasm sensitive detail...
FGFR3 F386L Debio 1347 myeloid neoplasm sensitive detail...
FGFR3 wild-type SU5402 myeloid neoplasm sensitive detail...
FGFR3 K650E SU5402 myeloid neoplasm sensitive detail...
FGFR3 rearrange PRN1371 myeloid neoplasm sensitive detail...
FGFR3 Y373C RO4987655 myeloid neoplasm no benefit detail...
FGFR3 Y373C RO5126766 myeloid neoplasm no benefit detail...
FGFR3 Y373C Selumetinib myeloid neoplasm no benefit detail...
FGFR3 rearrange AZD4547 myeloid neoplasm sensitive detail...
Unknown unknown Bortezomib + Dexamethasone + Lenalidomide myeloid neoplasm not applicable detail...
ETV6 - ABL1 Dasatinib myeloid neoplasm predicted - sensitive detail...
ETV6 - ABL1 Nilotinib myeloid neoplasm predicted - sensitive detail...
IDH1 mutant Ivosidenib + Venetoclax myeloid neoplasm predicted - sensitive detail...
IDH1 mutant Azacitidine + Ivosidenib + Venetoclax myeloid neoplasm predicted - sensitive detail...
JAK2 rearrange Ruxolitinib myeloid neoplasm sensitive detail...
JAK2 rearrange Fedratinib myeloid neoplasm sensitive detail...
ABL1 rearrange Dasatinib myeloid neoplasm sensitive detail...
ABL1 rearrange Nilotinib myeloid neoplasm sensitive detail...
ABL1 rearrange Imatinib myeloid neoplasm sensitive detail...
ABL1 rearrange Bosutinib myeloid neoplasm sensitive detail...
ABL1 rearrange Ponatinib myeloid neoplasm sensitive detail...
FLT3 rearrange Gilteritinib myeloid neoplasm sensitive detail...
FLT3 rearrange Midostaurin myeloid neoplasm sensitive detail...
FLT3 rearrange Sorafenib myeloid neoplasm sensitive detail...
FLT3 rearrange Sunitinib myeloid neoplasm sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed
NCT02420860 Phase II Famotidine Elotuzumab + Lenalidomide Diphenhydramine Dexamethasone Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT) Recruiting
NCT02506959 Phase II Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Recruiting
NCT02843074 Phase II Dexamethasone + Elotuzumab + Lenalidomide Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients Active, not recruiting
NCT02969837 Phase II Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma Recruiting
NCT03531918 Phase Ib/II Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm Recruiting
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT04189445 Phase II Futibatinib Futibatinib in Patients With Specific FGFR Aberrations Not yet recruiting
NCT04195945 Phase II CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Recruiting